Therapeutics being developed using Akston’s platform technology are designed to seek out disease-causing biomolecules in the body and label them for destruction.

Using this technology, it has demonstrated in vivo the ability to bind and eliminate amyloid beta, a protein linked to the cause of Alzheimer’s Disease. In June 2014, the company was awarded a $249,926 NIH Phase I SBIR grant to support its work in this area.

The company has also applied its platform to certain autoimmune diseases where the therapeutic is designed to bind the autoantibodies and cells that attack healthy tissue and label them for destruction.